See the DrugPatentWatch profile for Calquence
Calquence is a brand name for the drug acalabrutinib, a medication used to treat certain types of cancer [1]. It is a type of targeted therapy that works by inhibiting a protein called Bruton's tyrosine kinase (BTK), which plays a role in the growth and survival of certain cancer cells, particularly B-cell malignancies [1].
What types of cancer does Calquence treat?
Calquence is approved for the treatment of adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) [2]. CLL and SLL are essentially the same disease, differing only in the number of lymphocytes found in the blood or bone marrow [2]. MCL is a rare and aggressive type of non-Hodgkin lymphoma [2].
How does Calquence work?
Calquence is a selective BTK inhibitor. By blocking BTK, it disrupts signaling pathways essential for the proliferation and survival of malignant B-cells [1]. This action helps to control or eliminate the cancerous cells [1].
What are the potential side effects of Calquence?
Common side effects of Calquence can include diarrhea, fatigue, headache, muscle pain, bruising, and rash [1]. More serious side effects may include infections, bleeding events, heart rhythm problems (atrial fibrillation or flutter), high blood pressure, and secondary cancers [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
How long does it take for Calquence to work?
The time it takes for Calquence to start working can vary depending on the individual and the specific type and stage of cancer being treated [1]. Patients typically begin to see a reduction in cancer symptoms or disease progression after starting treatment, with full effects becoming apparent over time [1].
When does the patent for Calquence expire?
Information regarding the specific patent expiry dates for Calquence (acalabrutinib) is available through specialized drug patent databases. Websites like DrugPatentWatch.com provide detailed information on patent status and exclusivity for pharmaceutical products [3].
Are there alternative treatments for CLL, SLL, or MCL?
Yes, there are several alternative treatment options for CLL, SLL, and MCL, depending on the stage of the disease, patient health, and prior treatments. These can include other targeted therapies, chemotherapy, immunotherapy, and stem cell transplantation [4]. Your doctor will determine the most appropriate treatment plan for your specific situation.